Cingulate currently has two product candidates for the treatment of attention deficit hyperactivity disorder (ADHD).

Its lead product candidate, CTx-1301, utilizes the company’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved in the USA for the treatment of ADHD.

The company is headquartered in Kansas City, USA.